StockData
Veracyte, Inc. logo

Veracyte, Inc. (VCYT) stock

VCYTNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 16/3029% below fair value
$25.57+1.34 (+5.53%)

Close on Nov 18, 2026Market cap $2.06BP/E 18.3Yield –

Earnings

Veracyte's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Feb 24, 2027
Q4 FY2026 · estimated, during market hours
Revenue, Q3 FY2026
$151.80M
+15.1% on a year earlier
Non-GAAP diluted net earnings per common share, Q3 FY2026
$0.51
$0.51 a year earlier
Latest guidance
Raised
Nov 4, 2026 · 2 items

Quarterly results

Revenue and earnings per share from each of Veracyte's earnings releases, newest first

QuarterReportedRevenueYoYEPSAdj. EPSSource
Q4 FY2026ended Dec 31, 2026Feb 24, 2027Expected–––––
Q3 FY2026ended Sep 30, 2026Nov 4, 2026after the close$151.80M+15.1%$0.38$0.51Release
Q2 FY2026ended Jun 30, 2026Jul 30, 2026during market hours$150.30M+15.4%$0.31$0.54Release
Q1 FY2026ended Mar 31, 2026May 5, 2026during market hours$139.10M+21.5%$0.35$0.52Release
Q4 FY2025ended Dec 31, 2025Feb 25, 2026during market hours$140.60M+18.5%$0.51$0.53Release
Q3 FY2025ended Sep 30, 2025Nov 4, 2025during market hours$131.90M+13.8%$0.24$0.51Release
Q2 FY2025ended Jun 30, 2025Aug 6, 2025during market hours$130.20M+13.8%-$0.01$0.44Release
Q1 FY2025ended Mar 31, 2025May 7, 2025during market hours$114.50M+18.3%$0.09$0.31Release
Q4 FY2024ended Dec 31, 2024Feb 24, 2025during market hours$118.60M+20.8%$0.06$0.36Release
Q3 FY2024ended Sep 30, 2024Nov 6, 2024during market hours$115.90M+28.6%$0.19$0.33Release
Q2 FY2024ended Jun 30, 2024Aug 6, 2024during market hours$114.40M+26.7%$0.07$0.30Release
Q1 FY2024ended Mar 31, 2024May 7, 2024during market hours$96.80M+17.5%-$0.02–Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

Veracyte's latest outlook for periods it has not reported yet, compared with what it said before

MetricPeriodGuidanceBeforeChangeGiven
total revenueFY2026$590.00M – $596.00M$582.00M – $592.00MRaisedJul 30, 2026
total revenueGAAPFY2026$570.00M – $582.00M–NewFeb 25, 2026
total revenue growthFY2026+14% – +15%+13% – +14%LoweredJul 30, 2026
total revenue guidanceFY2026$590.00M – $593.00M–NewNov 4, 2026
adjusted EBITDA marginnon-GAAPFY202626%–NewMay 5, 2026
adjusted EBITDA marginnon-GAAPFY202626%25%RaisedNov 4, 2026
adjusted EBITDA marginnon-GAAPFY202626%–NewJul 30, 2026
adjusted EBITDA marginnon-GAAPFY202625%–NewJan 12, 2026
testing revenueFY2026$576.00M – $582.00M–NewJul 30, 2026
testing revenue growthFY2026+17% – +18%–NewJul 30, 2026

Guidance vs results

The last range Veracyte gave before each report, against the figure it then reported. Full years add up the four quarters.

PeriodMetricGuidanceActualResult
FY2025Revenue$484.00M – $487.00M$517.20MΣ4QAbove range
FY2025Revenue growth+16%+16.04%Σ4QWithin range

Guidance history

Every forecast Veracyte put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Nov 4, 2026adjusted EBITDA marginFY202626%Raised
Nov 4, 2026total revenue guidanceFY2026$590.00M – $593.00MNew
Jul 30, 2026adjusted EBITDA marginFY202626%New
Jul 30, 2026testing revenue growthFY2026+17% – +18%New
Jul 30, 2026testing revenueFY2026$576.00M – $582.00MNew
Jul 30, 2026total revenue growthFY2026+14% – +15%Lowered
Jul 30, 2026total revenueFY2026$590.00M – $596.00MRaised
May 5, 2026adjusted EBITDA marginFY202626%New
May 5, 2026total revenue growthFY2026+13% – +14%Lowered
May 5, 2026testing revenue growthFY2026+16% – +18%Raised
May 5, 2026total revenueFY2026$582.00M – $592.00MRaised
May 5, 2026testing revenueFY2026$570.00M – $580.00MLowered
Feb 25, 2026adjusted EBITDA marginFY202625%New
Feb 25, 2026total revenueFY2026$570.00M – $582.00MNew
Jan 12, 2026adjusted EBITDA marginFY202625%New
Jan 12, 2026total revenue guidanceFY2026+10% – +13%New
Jan 12, 2026testing revenue guidanceFY2026+14% – +16%Raised
Jan 12, 2026total revenue guidanceFY2026$570.00M – $582.00MNew
Jan 12, 2026testing revenue guidanceFY2026$559.00M – $569.00MLowered
Nov 4, 2025adjusted EBITDA as a percentage of revenueFY202525%New

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases Veracyte filed with the SEC as exhibits to Form 8-K or 6-K

  1. Results
  2. Update
  3. Results
  4. Results
  5. Results
  6. Results
  7. Results
  8. Results
  9. Results
  10. Results
  11. Results
  12. Results
  13. Results
  14. Results
  15. Results

See a number that looks wrong?